18F-FDG PET/CT 在乳腺癌中的应用:初始分期基于证据的推荐
本综述系统检索 MEDLINE 中至少 30 例患者的研究,总结 18F-FDG PET/CT 在乳腺癌分期中的证据并给出推荐。Ⅲ级证据支持用于新诊断乳腺癌初始分期(弱推荐),Ⅱ级证据支持用于局部晚期乳腺癌初始分期(强推荐);不推荐用于所有早期乳腺癌分期。基线肿瘤代谢信息与肿瘤生物学及预后相关(Ⅱ级证据)。
要点
- 局部晚期乳腺癌初始分期:Ⅱ级证据支持 18F-FDG PET/CT,强推荐。
- 新诊断乳腺癌初始分期:Ⅲ级证据支持 18F-FDG PET/CT,弱推荐。
- 不推荐 18F-FDG PET/CT 用于所有早期乳腺癌的分期。
核心结论
- 18F-FDG PET/CT 不推荐用于所有早期乳腺癌分期,但区域和全身分期改善的证据支持其用于局部晚期乳腺癌。
- 基线肿瘤糖酵解活性与肿瘤生物学和预后相关。
研究设计与样本
- 系统检索 MEDLINE,纳入报告至少 30 例患者的研究,按问题/人群、干预、比较和结局框架设计临床问题。
- 对入选文献进行批判性审阅,并制作证据表,将信息结构化为方法学、结果和局限性。
- 总结 18F-FDG PET/CT 在不同情境中使用的证据等级和推荐等级。
诊断标准与关键数值
- 新诊断乳腺癌初始分期:Ⅲ级证据支持使用 18F-FDG PET/CT,其诊断和治疗影响足以构成弱推荐。
- 局部晚期乳腺癌初始分期:Ⅱ级证据支持使用 18F-FDG PET/CT,其诊断和治疗影响足以构成强推荐。
- 新诊断乳腺癌基线 18F-FDG PET/CT 的代谢信息与肿瘤生物学相关并具有预后意义,由Ⅱ级证据支持。
临床应用与阅片要点
- 作者基于证据建议:局部晚期乳腺癌初始分期使用 18F-FDG PET/CT(强推荐)。
- 作者基于证据建议:新诊断乳腺癌初始分期使用 18F-FDG PET/CT(弱推荐)。
- 作者不推荐 18F-FDG PET/CT 用于所有早期乳腺癌的分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Current guidelines do not systematically recommend 18F-FDG PET/CT for breast cancer staging; and the recommendations and level of evidence supporting its use in different groups of patients vary among guidelines. This review summarizes the evidence about the role of 18F-FDG PET/CT in breast cancer staging and the therapeutic and prognostic impact accumulated in the last decade. Other related aspects, such as the association of metabolic information with biology and prognosis are considered and evidence-based recommendations for the use of 18F-FDG PET/CT in breast cancer staging are offered. We systematically searched MEDLINE for articles reporting studies with at least 30 patients related to clinical questions following the Problem/Population, Intervention, Comparison, and Outcome framework. We critically reviewed the selected articles and elaborated evidence tables structuring the summarized information into methodology, results, and limitations. The level of evidence and the grades of recommendation for the use of 18F-FDG PET/CT in different contexts are summarized. Level III evidence supports the use of 18F-FDG PET/CT for initial staging in patients with recently diagnosed breast cancer; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a weak recommendation in this population. In patients with locally advanced breast cancer, level II evidence supports the use of 18F-FDG PET/CT for initial staging; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a strong recommendation in this population. In patients with recently diagnosed breast cancer, the metabolic information from baseline 18F-FDG PET/CT is associated with tumor biology and has prognostic implications, supported by level II evidence. In conclusion, 18F-FDG PET/CT is not recommended for staging all patients with early breast cancer, although evidence of improved regional and systemic staging supports its use in locally advanced breast cancer. Baseline tumor glycolytic activity is associated with tumor biology and prognosis.
引用
- Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, et al. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumour Biol. 2017. PMID: 29025377. doi:10.1177/1010428317728285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。